氨酚羟考酮联合普瑞巴林治疗腰椎间盘突出症155例

Oxycodone and Acetaminophen Combined with Pregabalin in Treatment of 155 Case of Lumbar Disc Herniation

目的观察普瑞巴林联合氨酚羟考酮治疗腰椎间盘突出症的有效性及不良反应。方法选择2012年1月—2014年1月骨科门诊就诊的腰椎间盘突出症患者309例,随机数字表法分为治疗组155例和对照组154例。治疗组给予普瑞巴林,第1,2天75 mg,po,bid;第3天为150 mg,bid,并维持此剂量,疗程2周;氨酚羟考酮330 mg,po,tid,疗程2周。对照组给予氨酚羟考酮,330 mg,po,tid,疗程2周。利用疼痛、麻木视觉模拟评分(VAS)和直腿抬高试验进行疗效分析,观察治疗过程中不良反应发生情况。结果治疗1周后,两组患者疼痛、麻木较治疗前均有改善(P<0.05),治疗组优于对照组(P<0.05);治疗2周后,对照组直腿抬高试验阳性率9.74%,治疗组为3.87%(P<0.05);对照组不良反应发生率10.4%,治疗组为11.0%(P>0.05)。结论普瑞巴林联合氨酚羟考酮治疗腰椎间盘突出症患者疼痛、麻木缓解更显著,起效快,不良反应小。

Objective To observe the effectiveness and adverse reactions of oxycodone and acetaminophen combined with pregabalin for the treatment of lumbar disc heriation. Methods Three hundred and nine patients with lumbar disc herniation on orthopedic clinic from January 2012 to January 2014 were enrolled, which were divided into treatment group （n = 155） and control group（n= 154） with randomization. The treatment group received pregabalin（75 mg ,po,bid ,for the first and second day, and 150 mg,po,bid from the third day） combined with oxycodone and acetaminophen tablets （330 mg, po, tid）, while the control group was given pure oxycodone and aeetaminophen tablets （330 mg, po, tid）. The visual analog scale of pain, numbness, and straight leg raising test were used for efficacy analysis, and to observe whether there were adverse reactions during the treatment. Results After one week of treatment, pain and numbness of patients in both groups were improved（P〈0.05）, and the treatment group had better effect than the control group（ P〈0.05 ）. After two weeks of treatment, the straight leg raising test positive rate of the treatment group was 3.87%, which was lower than the control group with the rate of 9.74% （P〈0.05）. The adverse reactions incidences of two groups were 10.4% and 11.0% for control group and treatment group, respectively（ P〉 0.05）. Conclusion Oxycodone and acetaminophen tablets combined with pregabalin can better alleviate the pain and numbness of the patients with more rapid onset without rise of adverse reaction.